Rapamycin-d3

An internal standard for the quantification of rapamycin

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
500ug

￥1837.00

1470.00

- +
1mg

￥2775.00

2220.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajcx23396
CAS: 392711-19-2
别名: 三氘代雷帕霉素,Sirolimus-d3; AY-22989-d3
分子式: C51H76D3NO13
分子量: 917.2
纯度: >98%
溶解度: Chloroform: 5 mg/ml,DMSO: 25 mg/ml,Ethanol: 50 mg/ml,Methanol: 25 mg/ml
储存: Store at -20°C
库存: 现货

Background

Rapamycin-d₃ is intended for use as an internal standard for the quantification of rapamycin by GC- or LC-MS. Rapamycin is an allosteric inhibitor of the mammalian target of rapamycin (mTOR) complex 1 (mTORC1).¹ It interacts with FKBP prolyl isomerase 1A (FKBP12) to form a complex that binds to and inhibits the kinase activity of mTORC1. Rapamycin inhibits growth of Rh1 and Rh30 rhabdomyosarcoma cells in serum-free medium, with 50% inhibition observed at concentrations of 0.1 and 0.5 ng/ml, respectively, and increases apoptosis in these cells at 100 ng/ml.² It also induces autophagy in a variety of cell types.¹ Rapamycin inhibits IL-2-induced proliferation of IL-2-dependent T cells by 50% when used at concentrations less than 5 pM.³ Formulations containing rapamycin have been used as immunosuppressive agents in the prevention of organ transplant rejection.

1.Kim, Y.C., and Guan, K.-L.mTOR: A pharmacological target for autophagy regulationJ. Clin. Invest.125(1)25-32(2015) 2.Hosoi, H., Dilling, M.B., Shikata, T., et al.Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cellsCancer Res.59(4)886-894(1999) 3.Kay, J.E., Kromwel, L., Doe, S.E.A., et al.Inhibition of T and B lymphocyte proliferation by rapamycinImmunology72(4)544-549(1991)